The purpose of this study is to learn about the effects of the study medicine calledPaxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.This study will use patient health records in Ontario, to find people who were sick withCOVID-19 and visited a pharmacist to be treated, anytime from December 1st, 2022, toMarch 31st, 2024. To be included in our study, the people must be over 18 years of ageand be registered in the Ontario health system for at least one year. People were notincluded in our study if they have been pregnant in the past year or have serious kidneyor liver disease.We will separate the people in the study into two groups: those who received treatmentwith Paxlovid [nirmatrelvir-ritonavir/PF-07321332] and those who received no treatment.We will monitor their healthcare visits or if they die for any reason, for up to 60 daysafter the date that they visited their pharmacist. Then we will compare participantexperiences when they are taking the study medicine to when they are not. This will helpus determine if the study medicine is effective.
Not Provided
Drug: nirmatrelvir-ritonavir
Participants who were assessed with Covid prescribed and subsequently dispensed
nirmatrelvir-ritonavir during the selection period
Other Name: paxlovid
Other: No treatment
Participants who were assessed with Covid for nirmatrelvir-ritonavir but either were not
prescribed the medication or did not have it dispensed during the selection period
Inclusion
- Record of at least 1 nirmatrelvir-ritonavir prescription and at least 1 dispensation
issued by the pharmacist (Treated Cohort only) within 5 days of prescription,
identified through pharmacy billing codes
- Record of at least 1 assessment for nirmatrelvir-ritonavir, without a prescription
issued by the pharmacist (Untreated Cohort only), OR record of at least 1
prescription for nirmatrelvir-ritonavir without dispensation (Untreated Cohort
only), identified through pharmacy billing codes
Exclusion
- Invalid or incomplete records (e.g., missing age, missing sex, death before index)
- Record of a positive PCR test for SARS-CoV-2 between 5 and 90 days prior to the
index date
- Had a prescription for antivirals within 3 days prior to or on the index date
Pfizer New York
New York, New York, United States
Pfizer CT.gov Call Center, Study Director
Pfizer